<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Glimepiride: Drug information</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Glimepiride: Drug information</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="drugTitle">Glimepiride: Drug information</div><div class="clear"></div><div id="topicText">(For additional information <a class="drug drug_patient" data-topicid="12510" href="/d/html/12510.html" rel="external">see "Glimepiride: Patient drug information"</a>)<br/><br/>For abbreviations, symbols, and age group definitions used in Lexicomp (<a class="graphic graphic_table" href="/d/html/57469.html" rel="external">show table</a>)<div class="visuallyHidden drugH1Div" id="formulinkBodyPlaceholder"><span class="drugH1"></span></div>
<div class="list ubnlist drugH1Div drugBrandNames" id="F176236"><span class="drugH1">Brand Names: US</span>
<ul>
<li>Amaryl [DSC]</li></ul></div>
<div class="list canbnlist drugH1Div drugBrandNames" id="F52867050"><span class="drugH1">Brand Names: Canada</span>
<ul>
<li>APO-Glimepiride [DSC];</li>
<li>GEN-Glimepiride;</li>
<li>SANDOZ Glimepiride</li></ul></div>
<div class="ex_sect_xr thclist drugH1Div drugBrandNames" id="F176273"><span class="drugH1">Pharmacologic Category</span>
<ul>
<li>
                        Antidiabetic Agent, Sulfonylurea</li></ul></div>
<div class="block doa drugH1Div" id="F176241"><span class="drugH1">Dosing: Adult</span>
<div class="collapsible-indication">
<span class="collapsible-indication-title" data-indication-id="2ad35dab-7cea-4ec1-88c5-ab393b3cfc22">Diabetes mellitus, type 2, treatment</span>
<div class="collapsible-indication-wrap">
<p style="text-indent:-2em;margin-left:2em;">
<b>Diabetes mellitus, type 2, treatment:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Note:</b> May be used as an adjunctive agent or alternative monotherapy for patients in whom initial therapy with lifestyle intervention and metformin failed <b>or</b> who cannot take metformin. Sulfonylureas are associated with a greater risk of hypoglycemia than other noninsulin antidiabetic agents; if one is chosen, a sulfonylurea with a lower relative risk of hypoglycemia (eg, glimepiride, glipizide) is preferred (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-32022600','lexi-content-ref-ADA.1','lexi-content-ref-30291106']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-32022600','lexi-content-ref-ADA.1','lexi-content-ref-30291106'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<b>Oral:</b> Initial: 1 to 2 mg once daily with the first main meal; in patients whose glycemic levels are close to goal, use lower initial doses (eg, 1 mg once daily) to reduce the risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10454950','lexi-content-ref-10605995','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10454950','lexi-content-ref-10605995','lexi-content-ref-Manu.1'])">Ref</a></span>). In patients with severe hyperglycemia (eg, fasting glucose &gt;250 mg/dL, HbA<sub>1c</sub> &gt;9%) without ketonuria or spontaneous weight loss <b>and</b> in whom type 1 diabetes mellitus is unlikely, some experts use a higher initial dose of 4 to 8 mg once daily (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.1','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.1','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Dosage adjustment:</i> May increase dose in 1 to 2 mg increments every 1 to 4 weeks if needed to achieve glycemic goals; usual maintenance dose: 2 to 4 mg/day (maximum: 8 mg/day) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-10454950','lexi-content-ref-25132212','lexi-content-ref-Wexler.3','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-10454950','lexi-content-ref-25132212','lexi-content-ref-Wexler.3','lexi-content-ref-Manu.1'])">Ref</a></span>). <b>Note:</b> Increasing dosage from 4 to 8 mg/day may only provide modest glycemic benefit (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8842603']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8842603'])">Ref</a></span>). The 8 mg/day dosage may be administered in 1 or 2 divided doses (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8908379']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8908379'])">Ref</a></span>).</p></div>
</div>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<b>Dosage adjustment for concomitant therapy:</b> Significant drug interactions exist, requiring dose/frequency adjustment or avoidance. Consult drug interactions database for more information.</p></div>
<div class="block dora drugH1Div" id="F50990436"><span class="drugH1">Dosing: Kidney Impairment: Adult</span>
<p style="text-indent:0em;display:inline">The renal dosing recommendations are based upon the best available evidence and clinical expertise. Senior Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Altered kidney function:</b></p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &gt;60 mL/minute/1.73 m<sup>2</sup>: No dosage adjustment necessary.</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR 15 to 60 mL/minute/1.73 m<sup>2</sup>: Renal clearance of active metabolites may be reduced, leading to increased risk of hypoglycemia; consider initiating at a low dose (eg, 1 mg daily) and titrating cautiously (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-8960852','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-8960852','lexi-content-ref-Expert.DOR','lexi-content-ref-Manu.1'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:4em;">eGFR &lt;15 mL/minute/1.73 m<sup>2</sup>: Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); agents other than sulfonylureas are preferred due to risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1','lexi-content-ref-32998798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1','lexi-content-ref-32998798'])">Ref</a></span>). However, if a sulfonylurea is used, agents with a shorter half-life and no active metabolites (eg, glipizide) may be preferred to reduce the risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27967230','lexi-content-ref-28465376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27967230','lexi-content-ref-28465376'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Hemodialysis, intermittent (thrice weekly):</b> Unlikely to be significantly dialyzable (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); agents other than sulfonylureas are preferred due to risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1','lexi-content-ref-32998798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1','lexi-content-ref-32998798'])">Ref</a></span>). However, if a sulfonylurea is used, agents with a shorter half-life and no active metabolites (eg, glipizide) may be preferred to reduce the risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27967230','lexi-content-ref-28465376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27967230','lexi-content-ref-28465376'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Peritoneal dialysis:</b> Unlikely to be significantly dialyzable (highly protein bound) (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>):</p>
<p style="text-indent:-2em;margin-left:4em;">Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>); agents other than sulfonylureas are preferred due to risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.1','lexi-content-ref-32998798']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.1','lexi-content-ref-32998798'])">Ref</a></span>). However, if a sulfonylurea is used, agents with a shorter half-life and no active metabolites (eg, glipizide) may be preferred to reduce the risk of hypoglycemia (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-27967230','lexi-content-ref-28465376']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-27967230','lexi-content-ref-28465376'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>CRRT: </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>PIRRT (eg, sustained, low-efficiency diafiltration): </b>Avoid use (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Expert.DOR']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Expert.DOR'])">Ref</a></span>).</p></div>
<div class="block doha drugH1Div" id="F50987621"><span class="drugH1">Dosing: Hepatic Impairment: Adult</span>
<p style="text-indent:0em;margin-left:0em;display:inline">There are no dosage adjustments provided in the manufacturer’s labeling (has not been studied). Titrate carefully due to potential for increased hypoglycemia in patients with hepatic impairment.</p></div>
<div class="block doe drugH1Div" id="F176242"><span class="drugH1">Dosing: Older Adult</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note: </b>Use of sulfonylureas (eg, glimepiride) is associated with increased risk of hypoglycemia. The American Diabetes Association suggests using sulfonylureas with caution, and notes preference for glimepiride (or glipizide) due to lower relative risk of hypoglycemia compared to other sulfonylureas (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-ADA.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-ADA.2'])">Ref</a></span>).</p>
<p style="text-indent:-2em;margin-left:2em;">In cases where glimepiride is used, initiate at 1 mg once daily and monitor closely (<span class="ref-callout-list"><a aria-label="list of references" class="ref-callout-list-link" lexi-content-ref-id="['lexi-content-ref-Wexler.2']" onclick="event.preventDefault(); window.mobileOpenReferences &amp;&amp; mobileOpenReferences(['lexi-content-ref-Wexler.2'])">Ref</a></span>).</p></div>
<div class="block adr drugH1Div" id="F176204"><span class="drugH1">Adverse Reactions</span>
<p style="text-indent:0em;display:inline">The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.</p>
<p style="text-indent:-2em;margin-left:2em;">&gt;10%: Endocrine &amp; metabolic: Hypoglycemia (4% to 20%)</p>
<p style="text-indent:-2em;margin-left:2em;">1% to 10%:</p>
<p style="text-indent:-2em;margin-left:4em;">Central nervous system: Dizziness (2%), headache</p>
<p style="text-indent:-2em;margin-left:4em;">Gastrointestinal: Nausea (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Hepatic: Increased serum ALT (2%)</p>
<p style="text-indent:-2em;margin-left:4em;">Respiratory: Flu-like symptoms (5%)</p>
<p style="text-indent:-2em;margin-left:4em;">Miscellaneous: Accidental injury (6%)</p>
<p style="text-indent:-2em;margin-left:2em;">&lt;1%, postmarketing, and/or case reports: Abnormal hepatic function tests, accommodation disturbance (early treatment), agranulocytosis, alopecia, anaphylaxis, angioedema, aplastic anemia, cholestatic jaundice, diarrhea, disulfiram-like reaction, dysgeusia, dyspnea, erythema, gastrointestinal pain, hemolytic anemia, hepatic failure, hepatic insufficiency, hepatic porphyria, hepatitis, hypersensitivity, hypersensitivity angiitis, hyponatremia, hypotension, immune thrombocytopenia, leukopenia, maculopapular rash, morbilliform rash, pancytopenia, porphyria cutanea tarda, pruritus, shock, SIADH, skin photosensitivity, Stevens-Johnson syndrome, thrombocytopenia, urticaria, vomiting, weight gain</p></div>
<div class="block coi drugH1Div" id="F176219"><span class="drugH1">Contraindications</span>
<p style="text-indent:-2em;margin-left:2em;">Hypersensitivity to glimepiride, any component of the formulation, or sulfonamides</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Note:</b> Although the FDA-approved product labeling states this medication is contraindicated in patients with hypersensitivity to sulfonamide-containing drugs, the scientific basis of this cross-sensitivity has been challenged. See “Warnings/Precautions” for more detail.</p>
<p style="text-indent:-2em;margin-left:2em;margin-top:2em;">
<i>Canadian labeling:</i> Additional contraindications (not in US labeling): Pregnancy; breastfeeding; type 1 diabetes; diabetic ketoacidosis (with or without coma); severe renal or hepatic impairment</p></div>
<div class="block war drugH1Div" id="F176201"><span class="drugH1">Warnings/Precautions</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Concerns related to adverse effects:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Cardiovascular mortality: Product labeling states oral hypoglycemic drugs may be associated with an increased cardiovascular mortality as compared to treatment with diet alone or diet plus insulin. Data to support this association are limited, and several studies, including a large prospective trial (UKPDS 1998), have not supported an association. In a prospective, active-controlled study comparing linagliptin to glimepiride in patients with high baseline cardiovascular risk, the rates of cardiovascular events were similar over ~6 years (Rosenstock 2019). In patients with established atherosclerotic cardiovascular disease, other agents (eg, with demonstrated cardiovascular risk reduction) are preferred (ADA 2023).</p>
<p style="text-indent:-2em;margin-left:4em;">• Hypoglycemia: All sulfonylurea drugs are capable of producing severe hypoglycemia. Hypoglycemia is more likely to occur when caloric intake is deficient, after severe or prolonged exercise, when ethanol is ingested, or when more than one glucose-lowering drug is used. It is also more likely in elderly patients, malnourished patients, and in patients with impaired renal or hepatic function; use with caution.</p>
<p style="text-indent:-2em;margin-left:4em;">• Sulfonamide (“sulfa”) allergy: The FDA-approved product labeling for many medications containing a sulfonamide chemical group includes a broad contraindication in patients with a prior allergic reaction to sulfonamides. There is a potential for cross-reactivity between members of a specific class (eg, two antibiotic sulfonamides). However, concerns for cross-reactivity have previously extended to all compounds containing the sulfonamide structure (SO<sub>2</sub>NH<sub>2</sub>). An expanded understanding of allergic mechanisms indicates cross-reactivity between antibiotic sulfonamides and nonantibiotic sulfonamides may not occur or, at the very least, this potential is extremely low (Brackett 2004; Johnson 2005; Slatore 2004; Tornero 2004). In particular, mechanisms of cross-reaction due to antibody production (anaphylaxis) are unlikely to occur with nonantibiotic sulfonamides. T-cell-mediated (type IV) reactions (eg, maculopapular rash) are less well understood and it is not possible to completely exclude this potential based on current insights. In cases where prior reactions were severe (Stevens-Johnson syndrome/TEN), some clinicians choose to avoid exposure to these classes.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Disease-related concerns:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Bariatric surgery:</p>
<p style="text-indent:-2em;margin-left:6em;">– Altered absorption: Use IR formulations after surgery to minimize the potential effects of bypassing stomach and proximal small bowel with gastric bypass or more rapid gastric emptying and proximal small bowel transit with sleeve gastrectomy (Apovian 2015). ER formulations may have altered release and absorption patterns after gastric bypass or sleeve gastrectomy (but not gastric band). Compared to control, T<sub>max</sub> in a gastric bypass cohort administered tolbutamide was significantly shorter (1.4 ± 1.8 vs 5.1 ± 1.7 hours; <i>P </i>&lt; 0.001), while C<sub>max</sub> and AUC<sub>0-</sub>
<sub>∞</sub> were not altered (Tandra 2013).</p>
<p style="text-indent:-2em;margin-left:6em;">– Hypoglycemia: Use an antidiabetic agent without the potential for hypoglycemia if possible; hypoglycemia may occur after gastric bypass, sleeve gastrectomy, and gastric band (Mechanick 2020). Insulin secretion and sensitivity may be partially or completely restored after these procedures (gastric bypass is most effective, followed by sleeve, and finally band) (Korner 2009; Peterli 2012). First-phase insulin secretion and hepatic insulin sensitivity have been shown to be significantly improved in the immediate days after gastric bypass and sleeve gastrectomy. The restorative effects of these procedures on peripheral insulin sensitivity may occur later in the 3- to 12-month period postsurgery (Mingrone 2016).</p>
<p style="text-indent:-2em;margin-left:6em;">– Weight gain: Evaluate risk vs benefit and consider alternative therapy after gastric bypass, sleeve gastrectomy, and gastric banding; weight gain may occur (Apovian 2015).</p>
<p style="text-indent:-2em;margin-left:4em;">• Glucose-6-phosphate dehydrogenase (G6PD) deficiency: Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency may be at an increased risk of sulfonylurea-induced hemolytic anemia; however, cases have also been described in patients without G6PD deficiency during postmarketing surveillance. Use with caution and consider a nonsulfonylurea alternative in patients with G6PD deficiency.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hepatic impairment: Use with caution; patients with hepatic impairment are more likely to develop hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Renal impairment: Use with caution and reduce dosage; patients with renal impairment are more likely to develop hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:4em;">• Stress-related states: It may be necessary to discontinue therapy and administer insulin if the patient is exposed to stress (eg, fever, trauma, infection, surgery).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Special populations:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• CYP2C9 genotype: Systemic exposure of glimepiride is increased in patients with CYP2C9*3 allele (Niemi 2002).</p>
<p style="text-indent:-2em;margin-left:4em;">• Older adult: Use with caution; older adult patients are more likely to develop hypoglycemia.</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>
<i>Other warnings/precautions:</i></b></p>
<p style="text-indent:-2em;margin-left:4em;">• Appropriate use: Not indicated for use in patients with type 1 diabetes mellitus or with diabetic ketoacidosis.</p>
<p style="text-indent:-2em;margin-left:4em;">• Hospitalized patients: Consider temporary discontinuation of noninsulin antidiabetic agents and initiation or continuation of insulin therapy during hospitalization (ADA 2023). In noncritically ill hospitalized patients, continued use of glimepiride may be considered if there are no contraindications, regular nutritional intake is expected, and blood glucose is well controlled; close monitoring and subsequent dosage adjustments are recommended (ADA/AACE [Moghissi 2009]; Bogun 2013; Inzucchi 2006).</p></div>
<div class="block foc drugH1Div" id="F176211"><span class="drugH1">Dosage Forms: US</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.  [DSC] = Discontinued product</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amaryl: 1 mg [DSC] [scored]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Amaryl: 2 mg [DSC], 4 mg [DSC] [scored; contains fd&amp;c blue #2 (indigo carm) aluminum lake]</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 4 mg</p></div>
<div class="block geq drugH1Div" id="F176197"><span class="drugH1">Generic Equivalent Available: US</span>
<p style="text-indent:0em;display:inline">Yes</p></div>
<div class="block fee drugH1Div" id="F176221"><span class="drugH1">Pricing: US</span>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">
<b>Tablets</b> (Glimepiride Oral)</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">1 mg (per each): $0.40 - $1.08</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">2 mg (per each): $0.64 - $1.75</p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">4 mg (per each): $1.22 - $3.30</p>
<p style="text-indent:0em;">
<b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>
<div class="block dinfoc drugH1Div" id="F52867051"><span class="drugH1">Dosage Forms: Canada</span>
<p style="text-indent:0em;text-align:justify;display:inline">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>
<p style="text-indent:-2em;margin-left:2em;text-align:justify;">Tablet, Oral: </p>
<p style="text-indent:-2em;margin-left:4em;text-align:justify;">Generic: 1 mg, 2 mg, 4 mg</p></div>
<div class="block adm drugH1Div" id="F176216"><span class="drugH1">Administration: Adult</span>
<p style="text-indent:0em;display:inline">
<b>Oral:</b> Administer once daily with breakfast or first main meal of the day. Patients that are NPO or require decreased caloric intake may need doses held to avoid hypoglycemia.</p></div>
<div class="block use drugH1Div" id="F176215"><span class="drugH1">Use: Labeled Indications</span>
<p style="text-indent:0em;display:inline">
<b>Diabetes mellitus, type 2, treatment:</b> As an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus.</p></div>
<div class="block mst drugH1Div" id="F176280"><span class="drugH1">Medication Safety Issues</span>
<div class="collapsible">
<span class="collapsible-title">Sound-alike/look-alike issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Glimepiride may be confused with glipiZIDE.</p>
<p style="text-indent:-2em;margin-left:4em;">Amaryl may be confused with Altace, Amerge.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">High alert medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">The Institute for Safe Medication Practices (ISMP) includes this medication among its list of drugs which have a heightened risk of causing significant patient harm when used in error.</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">Older Adult: High-Risk Medication:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Avoid routine use of sulfonylureas due to increased risk of hypoglycemia; however, if a sulfonylurea is needed, one with a lower relative risk of hypoglycemia (eg, gliclazide, glimepiride, glipizide) is preferred (ADA 2022; Beers Criteria [AGS 2023]; Diabetes Canada 2018).</p></div>
</div>
<div class="collapsible">
<span class="collapsible-title">International issues:</span>
<div class="collapsible-wrap">
<p style="text-indent:-2em;margin-left:4em;">Amarel [France], Amaryl [US, Canada, and multiple international markets] may be confused with Reminyl brand name for galantamine [multiple international markets].</p>
<p style="text-indent:-2em;margin-left:4em;">Amaryl [US, Canada, and multiple international markets] may be confused with Almarl brand name for arotinolol [Japan].</p></div>
</div>
</div>
<div class="block cyt drugH1Div" id="F176267"><span class="drugH1">Metabolism/Transport Effects</span>
<p style="text-indent:0em;display:inline">
<b>Substrate</b> of CYP2C9 (major), OATP1B1/1B3 (SLCO1B1/1B3); <b>Note:</b> Assignment of Major/Minor substrate status based on clinically relevant drug interaction potential</p></div>
<div class="block dri drugH1Div" id="F176206"><span class="drugH1">Drug Interactions</span><br/><br/><div class="clear"></div><p xmlns=""></p><div class="inner" xmlns=""><p style="text-indent:0em;display:inline"><b>Note</b>: Interacting drugs may <b>not be individually listed below</b> if they are part of a group interaction (eg, individual drugs within “CYP3A4 Inducers [Strong]” are NOT listed).  For a complete list of drug interactions by individual drug name and detailed management recommendations, use the Lexicomp drug interactions program by clicking on the “Launch drug interactions program” link above.</p><p xmlns=""></p></div>
<p style="text-indent:-2em;margin-left:2em;">Ajmaline: Sulfonamides may enhance the adverse/toxic effect of Ajmaline. Specifically, the risk for cholestasis may be increased. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alcohol (Ethyl): Sulfonylureas may enhance the adverse/toxic effect of Alcohol (Ethyl). A flushing reaction may occur. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpelisib: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Glucosidase Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with an alpha-glucosidase inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Alpha-Lipoic Acid: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Systemic). <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Aminolevulinic Acid (Topical): Photosensitizing Agents may enhance the photosensitizing effect of Aminolevulinic Acid (Topical). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Amiodarone: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Androgens: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Antidiabetic Agents: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Beta1 Selective): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Beta-Blockers (Nonselective): May enhance the hypoglycemic effect of Sulfonylureas. Beta-Blockers (Nonselective) may diminish the therapeutic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Bortezomib: May enhance the therapeutic effect of Antidiabetic Agents. Bortezomib may diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Carbocisteine: Sulfonylureas may enhance the adverse/toxic effect of Carbocisteine. Specifically, sulfonylureas may enhance adverse effects of alcohol that is present in liquid formulations of carbocisteine-containing products. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Chloramphenicol (Systemic): May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Clarithromycin: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Colesevelam: May decrease the serum concentration of Glimepiride. Management: Administer glimepiride at least 4 hours prior to colesevelam.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inducers (Moderate): May decrease the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">CYP2C9 Inhibitors (Moderate): May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dexketoprofen: May enhance the adverse/toxic effect of Sulfonamides.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Dipeptidyl Peptidase-IV Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a dipeptidyl peptidase-IV inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Direct Acting Antiviral Agents (HCV): May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Elexacaftor, Tezacaftor, and Ivacaftor: May increase the serum concentration of Glimepiride.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Etilefrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Fibric Acid Derivatives: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Glucagon-Like Peptide-1 Agonists: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose reductions when used in combination with glucagon-like peptide-1 agonists.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Guanethidine: May enhance the hypoglycemic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Herbal Products with Glucose Lowering Effects: May enhance the hypoglycemic effect of Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hyperglycemia-Associated Agents: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: May enhance the hypoglycemic effect of other Hypoglycemia-Associated Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Hypoglycemia-Associated Agents: Antidiabetic Agents may enhance the hypoglycemic effect of Hypoglycemia-Associated Agents. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Lumacaftor and Ivacaftor: May decrease the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers). Lumacaftor and Ivacaftor may increase the serum concentration of CYP2C9 Substrates (High Risk with Inhibitors or Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Maitake: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mecamylamine: Sulfonamides may enhance the adverse/toxic effect of Mecamylamine. <i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Methoxsalen (Systemic): Photosensitizing Agents may enhance the photosensitizing effect of Methoxsalen (Systemic). <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Metreleptin: May enhance the hypoglycemic effect of Sulfonylureas. Management: Sulfonylurea dosage adjustments (including potentially large decreases) may be required to minimize the risk for hypoglycemia with concurrent use of metreleptin.  Monitor closely for signs or symptoms of hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Miconazole (Oral): May enhance the hypoglycemic effect of Sulfonylureas. Miconazole (Oral) may increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Mitiglinide: May enhance the adverse/toxic effect of Sulfonylureas.<i> Risk X: Avoid combination</i></p>
<p style="text-indent:-2em;margin-left:2em;">Monoamine Oxidase Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Pegvisomant: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Porfimer: Photosensitizing Agents may enhance the photosensitizing effect of Porfimer. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Probenecid: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Prothionamide: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Quinolones: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects. Quinolones may diminish the therapeutic effect of Agents with Blood Glucose Lowering Effects. Specifically, if an agent is being used to treat diabetes, loss of blood sugar control may occur with quinolone use.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Rifapentine: May decrease the serum concentration of CYP2C9 Substrates (High risk with Inducers).<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Ritodrine: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Salicylates: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Selective Serotonin Reuptake Inhibitors: May enhance the hypoglycemic effect of Agents with Blood Glucose Lowering Effects.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sodium-Glucose Cotransporter 2 (SGLT2) Inhibitors: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider a decrease in sulfonylurea dose when initiating therapy with a sodium-glucose cotransporter 2 (SGLT2) inhibitor and monitor patients for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Sulfonamide Antibiotics: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tetracyclines: May enhance the hypoglycemic effect of Sulfonylureas.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Tezacaftor and Ivacaftor: May increase the serum concentration of Glimepiride.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazide and Thiazide-Like Diuretics: May diminish the therapeutic effect of Antidiabetic Agents.<i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Thiazolidinediones: May enhance the hypoglycemic effect of Sulfonylureas. Management: Consider sulfonylurea dose adjustments in patients taking thiazolidinediones and monitor for hypoglycemia.<i> Risk D: Consider therapy modification</i></p>
<p style="text-indent:-2em;margin-left:2em;">Verteporfin: Photosensitizing Agents may enhance the photosensitizing effect of Verteporfin. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Vitamin K Antagonists (eg, warfarin): Sulfonylureas may enhance the anticoagulant effect of Vitamin K Antagonists. Vitamin K Antagonists may enhance the hypoglycemic effect of Sulfonylureas. <i> Risk C: Monitor therapy</i></p>
<p style="text-indent:-2em;margin-left:2em;">Voriconazole: May increase the serum concentration of Sulfonylureas.<i> Risk C: Monitor therapy</i></p></div>
<div class="block rep_considerations drugH1Div" id="F56092229"><span class="drugH1">Reproductive Considerations</span>
<p style="text-indent:0em;display:inline">Sulfonylureas are not recommended for patients with type 2 diabetes mellitus planning to become pregnant. Patients who could become pregnant should use effective contraception during therapy. Transition to a preferred therapy should be initiated prior to conception and contraception should be continued until glycemic control is achieved (ADA 2023; Alexopoulos 2019; Egan 2020)</p></div>
<div class="block pri drugH1Div" id="F176222"><span class="drugH1">Pregnancy Considerations</span>
<p style="text-indent:0em;">Information related to the use of glimepiride during pregnancy is limited (Balaguer Santamaría 2000; Kalyoncu 2005). Severe hypoglycemia lasting 4 to 10 days has been noted in infants born to mothers taking a sulfonylurea at the time of delivery. If exposure during pregnancy occurs, discontinue at least 2 weeks prior to delivery.</p>
<p style="text-indent:0em;margin-top:2em;">Poorly controlled diabetes during pregnancy can be associated with an increased risk of adverse maternal and fetal outcomes, including diabetic ketoacidosis, preeclampsia, spontaneous abortion, preterm delivery, delivery complications, major malformations, stillbirth, and macrosomia. To prevent adverse outcomes, prior to conception and throughout pregnancy, maternal blood glucose and HbA<sub>1c</sub> should be kept as close to target goals as possible but without causing significant hypoglycemia (ADA 2023; Blumer 2013).</p>
<p style="text-indent:0em;margin-top:2em;">Agents other than glimepiride are currently recommended to treat diabetes mellitus in pregnancy (ADA 2023).</p></div>
<div class="block brc drugH1Div" id="F5650825"><span class="drugH1">Breastfeeding Considerations</span>
<p style="text-indent:-2em;margin-left:2em;">It is not known if glimepiride is present in breast milk.</p>
<p style="text-indent:-2em;margin-left:2em;">According to the manufacturer, the decision to breastfeed during therapy should consider the risk of infant exposure, the benefits of breastfeeding to the infant, and benefits of treatment to the mother. Monitor the breastfed infant for signs of hypoglycemia.</p></div>
<div class="block dic drugH1Div" id="F176223"><span class="drugH1">Dietary Considerations</span>
<p style="text-indent:0em;display:inline">Take with breakfast or the first main meal of the day. Individualized medical nutrition therapy based on American Diabetes Association recommendations is an integral part of therapy.</p></div>
<div class="block mop drugH1Div" id="F176209"><span class="drugH1">Monitoring Parameters</span>
<p style="text-indent:-2em;margin-left:2em;">Monitor for signs and symptoms of hypoglycemia (fatigue, excessive hunger, profuse sweating, numbness of extremities), blood glucose; renal function.</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>HbA<sub>1c</sub></i>: Monitor at least twice yearly in patients who have stable glycemic control and are meeting treatment goals; monitor quarterly in patients in whom treatment goals have not been met, or with therapy change. <b>Note: </b>In patients prone to glycemic variability (eg, patients with insulin deficiency), or in patients whose HbA<sub>1c</sub> is discordant with serum glucose levels or symptoms, consider evaluating HbA<sub>1c</sub> in combination with blood glucose levels and/or a glucose management indicator (ADA 2023; KDIGO 2020).</p></div>
<div class="block rer drugH1Div" id="F176212"><span class="drugH1">Reference Range</span>
<p style="text-indent:-2em;margin-left:2em;">
<b>Recommendations for glycemic control in patients with diabetes:</b></p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Nonpregnant adults with diabetes (AACE [Samson 2023], ADA 2023):</i></p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% (a more aggressive [&lt;6.5%] or less aggressive [&lt;8%] HbA<sub>1c</sub> goal may be targeted based on patient-specific characteristics). <b>Note: </b>In patients using a continuous glucose monitoring system, a goal of time in range &gt;70% with time below range &lt;4% is recommended and is similar to a goal HbA<sub>1c</sub> &lt;7%.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:6em;">Peak postprandial capillary blood glucose (~1 to 2 hours after a meal): &lt;180 mg/dL (SI: &lt;10 mmol/L) (more or less stringent goals may be appropriate based on patient-specific characteristics).</p>
<p style="text-indent:-2em;margin-left:4em;">
<i>Older adults (≥65 years of age) (ADA 2023):</i>
<b>Note: </b>Consider less strict targets in patients who are using insulin and/or insulin secretagogues (sulfonylureas, meglitinides) (ES [LeRoith 2019]).</p>
<p style="text-indent:-2em;margin-left:6em;">HbA<sub>1c</sub>: &lt;7% to 7.5% (healthy); &lt;8% (complex/intermediate health). <b>Note:</b> Individualization may be appropriate based on patient and caregiver preferences and/or presence of cognitive impairment. In patients with very complex or poor health (ie, limited remaining life expectancy), consider making therapy decisions based on avoidance of hypoglycemia and symptomatic hyperglycemia rather than HbA<sub>1c</sub> level.</p>
<p style="text-indent:-2em;margin-left:6em;">Preprandial capillary blood glucose: 80 to 130 mg/dL (SI: 4.4 to 7.2 mmol/L) (healthy); 90 to 150 mg/dL (SI: 5 to 8.3 mmol/L) (complex/intermediate health); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:6em;">Bedtime capillary blood glucose: 80 to 180 mg/dL (SI: 4.4 to 10 mmol/L) (healthy); 100 to 180 mg/dL (SI: 5.6 to 10 mmol/L) (complex/intermediate health); 110 to 200 mg/dL (SI: 6.1 to 11.1 mmol/L) (very complex/poor health).</p>
<p style="text-indent:-2em;margin-left:2em;">
<b>Classification of hypoglycemia (ADA 2023):</b></p>
<p style="text-indent:-2em;margin-left:4em;">Level 1: 54 to 70 mg/dL; hypoglycemia alert value; initiate fast-acting carbohydrate (eg, glucose) treatment.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 2: &lt;54 mg/dL (SI: &lt;3 mmol/L); threshold for neuroglycopenic symptoms; requires immediate action.</p>
<p style="text-indent:-2em;margin-left:4em;">Level 3: Hypoglycemia associated with a severe event characterized by altered mental and/or physical status requiring assistance.</p></div>
<div class="block pha drugH1Div" id="F176200"><span class="drugH1">Mechanism of Action</span>
<p style="text-indent:0em;display:inline">Stimulates insulin release from the pancreatic beta cells; reduces glucose output from the liver; insulin sensitivity is increased at peripheral target sites</p></div>
<div class="block phk drugH1Div" id="F176218"><span class="drugH1">Pharmacokinetics (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Onset of action: Peak effect: Blood glucose reductions: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Duration: 24 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Absorption: 100%</p>
<p style="text-indent:-2em;margin-left:2em;">Distribution: V<sub>d</sub>: 8.8 L</p>
<p style="text-indent:-2em;margin-left:2em;">Protein binding: &gt;99.5%</p>
<p style="text-indent:-2em;margin-left:2em;">Metabolism: Hepatic oxidation via CYP2C9 to M1 metabolite (~33% activity of parent compound); further oxidative metabolism to inactive M2 metabolite</p>
<p style="text-indent:-2em;margin-left:2em;">Half-life elimination: 5 to 9 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Time to peak, plasma: 2 to 3 hours</p>
<p style="text-indent:-2em;margin-left:2em;">Excretion: Urine (60%, 80% to 90% as M1 and M2 metabolites); feces (40%, 70% as M1 and M2 metabolites)</p></div>
<div class="block phksp drugH1Div" id="F51196137"><span class="drugH1">Pharmacokinetics: Additional Considerations (Adult Data Unless Noted)</span>
<p style="text-indent:-2em;margin-left:2em;">Altered kidney function: As renal function declines, glimepiride serum levels decrease and metabolite (M1 and M2) AUC and half-lives increase. Patients with CrCl &lt;20 mL/minute had 2.3-fold higher AUC of M1 (an active metabolite) compared to patients with CrCl &gt;50 mL/minute.</p></div>
<div class="list fbnlist drugH1Div drugBrandNames" id="F176224"><span class="drugH1">Brand Names: International</span><div class="ibn-search drugBrandNames"></div>
<div class="collapsible-indication brand-names-accordion drugBrandNames"><span class="collapsible-indication-title">International Brand Names by Country</span><div class="collapsible-indication-wrap-frame drugBrandNames"><div class="collapsible-indication-wrap drugBrandNames">For country code abbreviations (<a class="graphic graphic_table" href="/d/html/116421.html" rel="external">show table</a>)<br xmlns=""/><br/><ul>
<li>
<span class="countryCode">(AE)</span> <span class="country">United Arab Emirates</span><span class="countrySeparator">: </span><span class="drugName">Adglim | Amaryl | Diapride | Econid | G pride | Glim | Glimepirid hexal | Glimulin | Glypride | Melital</span>;</li>
<li>
<span class="countryCode">(AR)</span> <span class="country">Argentina</span><span class="countrySeparator">: </span><span class="drugName">Adiuvan | Amaryl | Anotul | Endial | Glemaz | Gliperid | Gluceride | Glucopirida | Hipoglut | Islopir | Lomet</span>;</li>
<li>
<span class="countryCode">(AT)</span> <span class="country">Austria</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepirid | Glimepirid Actavis | Glimepirid stada | Glimestad</span>;</li>
<li>
<span class="countryCode">(AU)</span> <span class="country">Australia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Apo-Glimepiride | Aylide | Dimirel | Glimepiride an | Glimepiride ga | Pharmacor Glimepiride</span>;</li>
<li>
<span class="countryCode">(BD)</span> <span class="country">Bangladesh</span><span class="countrySeparator">: </span><span class="drugName">Adglim | Amaryl | Condia | Dactus | Dialon | Diaryl | Dieta | Gipid | Glemep | Glimirid | Glims | Glirid | Gluconor | Glucorid | Glutim | Limep | Limpet | Losucon | Mepid | SB glim | Secrin | Senride | Stimulin</span>;</li>
<li>
<span class="countryCode">(BE)</span> <span class="country">Belgium</span><span class="countrySeparator">: </span><span class="drugName">Amarylle | Dialosa | Glimepiride accord | Glimepiride Apotex</span>;</li>
<li>
<span class="countryCode">(BF)</span> <span class="country">Burkina Faso</span><span class="countrySeparator">: </span><span class="drugName">Adride | Amarel | Diabetan | Fairglim | Glimed | Irys | Odia</span>;</li>
<li>
<span class="countryCode">(BG)</span> <span class="country">Bulgaria</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Fertin | Glimecon | Glimegamma | Gliper | Meglimid</span>;</li>
<li>
<span class="countryCode">(BR)</span> <span class="country">Brazil</span><span class="countrySeparator">: </span><span class="drugName">Amaglyn | Amaryl | Azulix | Betes | Bioglic | Diabemed | Diamellits | Diamicron | Gliansor | Glimepibal | Glimepil | Glimepirida | Glimeprid | Glimeran | Glimesec | Glycopirida | Glymryl | Hipomeril</span>;</li>
<li>
<span class="countryCode">(CH)</span> <span class="country">Switzerland</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepirid Helvepharm | Glimepirid sandoz | Glimepirid teva | Glimepiride zentiva | Glimerax | Glimeryl Mepha</span>;</li>
<li>
<span class="countryCode">(CI)</span> <span class="country">Côte d'Ivoire</span><span class="countrySeparator">: </span><span class="drugName">Adride | Amarel | Diaglim | Glema | Glimed | Glimepiride denk | Glimepiride winthrop | Glimepro | Glimid | Glimsy 1 | Glimsy 2 | Glipiryl | Glyree | Limper | Odia</span>;</li>
<li>
<span class="countryCode">(CL)</span> <span class="country">Chile</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glemaz | Glimekem</span>;</li>
<li>
<span class="countryCode">(CN)</span> <span class="country">China</span><span class="countrySeparator">: </span><span class="drugName">A mo li | Amaryl | AN DUO MEI | An ni ping | Di bei | Jia he luo | Ke de ping | Li yi ping | Rui ping | Sheng ping | Wan su ping | Ya mo li | Yi rui | You su</span>;</li>
<li>
<span class="countryCode">(CO)</span> <span class="country">Colombia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepirida | Glimepirida denk | Glimepirida mk | Glimerid | Glucomet | Glucox</span>;</li>
<li>
<span class="countryCode">(CZ)</span> <span class="country">Czech Republic</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Apo glimepirid | Eglymad | Glimegamma | Glimepirid +Pharma | Glimepirid aurovitas | Glimepirid sandoz | Glymexan | Medopirid | Metis | Oltar</span>;</li>
<li>
<span class="countryCode">(DE)</span> <span class="country">Germany</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimegamma | Glimepirid | Glimepirid 1 a pharma | Glimepirid Aaa-Pharma | Glimepirid aristo | Glimepirid aurobindo | Glimepirid Heumann | Glimepiride accord | Glimepiride denk | Glimerid | Magna | Solosa</span>;</li>
<li>
<span class="countryCode">(DO)</span> <span class="country">Dominican Republic</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Amyline | Aramil | Diapride | Efinex | Euroglimep | Glandin | Glimepirida | Glimepirida mk | Glimepiril | Glimeryl | Glipiride | Glunor | Glutamical | Panabutol | Piglifar | Sinperan | Zoryl</span>;</li>
<li>
<span class="countryCode">(EC)</span> <span class="country">Ecuador</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glemaz | Gliansor | Glicivin | Glimepax | Glimepirida | Glimepirida mk</span>;</li>
<li>
<span class="countryCode">(EE)</span> <span class="country">Estonia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepirid Accord | Meglimid</span>;</li>
<li>
<span class="countryCode">(EG)</span> <span class="country">Egypt</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Amypride | Diabenor | Diabetless | Diabeto | Diabride | Dolcyl | Gedimadel | Glaryl | Glemax | Glimadel | Glimaryl | Glimeryl | Glimitoid | Gliperide | Glucoless | Glucoryl | Reglidib | Sugarfall</span>;</li>
<li>
<span class="countryCode">(ES)</span> <span class="country">Spain</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepirida Actavis | Glimepirida Apotex | Glimepirida aurobindo | Glimepirida Edigen | Roname</span>;</li>
<li>
<span class="countryCode">(ET)</span> <span class="country">Ethiopia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Euglim | Glimepiride denk | Glimeryl | Glimsure | Glimulin | Glypride | Nafuril | Piramyl | S glim</span>;</li>
<li>
<span class="countryCode">(FI)</span> <span class="country">Finland</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepirid bmm pharma | Glimepirid orion | Glimepirid Ratiopharm | Pirtad</span>;</li>
<li>
<span class="countryCode">(FR)</span> <span class="country">France</span><span class="countrySeparator">: </span><span class="drugName">Amarel | Glimepiride accord healthcare | Glimepiride actavis | Glimepiride Cristers | Glimepiride evolugen</span>;</li>
<li>
<span class="countryCode">(GB)</span> <span class="country">United Kingdom</span><span class="countrySeparator">: </span><span class="drugName">Amaryl</span>;</li>
<li>
<span class="countryCode">(GH)</span> <span class="country">Ghana</span><span class="countrySeparator">: </span><span class="drugName">Dexel</span>;</li>
<li>
<span class="countryCode">(GR)</span> <span class="country">Greece</span><span class="countrySeparator">: </span><span class="drugName">Adinsulin-S | Anovis | Glidil | Glimepirid teva | Glimepirid/Teva | Glimepiride actavis | Glimepiride/mylan | Glimepiron | Glimespes | Glincil | Gliperin | Glirid | Raltone | Solosa | Sucryl | Tetig | Tipo II</span>;</li>
<li>
<span class="countryCode">(GT)</span> <span class="country">Guatemala</span><span class="countrySeparator">: </span><span class="drugName">Daol</span>;</li>
<li>
<span class="countryCode">(HK)</span> <span class="country">Hong Kong</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Diapride | Getryl | Glimaryl | Glimeryl | NIKP Glimepiride</span>;</li>
<li>
<span class="countryCode">(HR)</span> <span class="country">Croatia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Betaglid | Diapirid | Dibiglim | Glimepirid PharmaS | Meglimid | Melpamid</span>;</li>
<li>
<span class="countryCode">(HU)</span> <span class="country">Hungary</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glempid | Glimebene | Glimegamma | Glimepirid Zentiva</span>;</li>
<li>
<span class="countryCode">(ID)</span> <span class="country">Indonesia</span><span class="countrySeparator">: </span><span class="drugName">Actaryl | Amadiab | Amaryl | Glamarol | Gliaride | Glimepix | Glimetic | Glimexal | Gliperid | Glucokaf | Glucoryl | Gluvas | Metrix | Pimaryl | Relide | Simryl | Velacom | Versibet</span>;</li>
<li>
<span class="countryCode">(IE)</span> <span class="country">Ireland</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepiride accord</span>;</li>
<li>
<span class="countryCode">(IL)</span> <span class="country">Israel</span><span class="countrySeparator">: </span><span class="drugName">Amaryl</span>;</li>
<li>
<span class="countryCode">(IN)</span> <span class="country">India</span><span class="countrySeparator">: </span><span class="drugName">Adride | Amaryl | Apriglim | Azulix | Betaglim | Blisto | Diaglim | Diapride | Dibiglim | Emperide | Enristas 1 | Enristas 2 | Euglim | Flexiglim | Geminor | Gepride | Glador | Glilar | Glim | Glimcare | Glimchek | Glimcip | Glimcom | Glimda | Glimefine | Glimeglu | Glimenorm | Glimer | Glimerin | Glimestar | Glimetop | Glimfirst | Glimfit | Glimicare | Glimicer | Glimicure | Glimicut | Glimid | Glimifix | Glimigraf | Glimimore | Gliminyle | Glimiprex | Glimiprime | Glimisave | Glimitab | Glimital | Glimiteo | Glimitrol | Glimixia | Glimkap | Glimp | Glimpid | Glimsite | Glimtab | Glimulin | Glimy | Glimz | Glipride | Glisen | Glisimet | Glitaray | Glucoryl | Glusens 2 | Glycipride | Glycirid | Glyfix | Glynamic | Glypar | Glypride | Glyree | Glytab | Gmr | Gp | GP 2 | Grid | Gride | Ilet | Imediab | Isryl | K-glim | Karmelitus | Limer | Maydine | Mepride | Mypride | Nabal | Normaglim | Olglimide | Prichek | Prides | Rioglim | Secretag | Semi amaryl | Sulfoglim | Supride | Ziglim | Zoryl</span>;</li>
<li>
<span class="countryCode">(IT)</span> <span class="country">Italy</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Diamel | Glimepiride Acc | Glimepiride actavis | Glimepiride eg | Solosa</span>;</li>
<li>
<span class="countryCode">(JO)</span> <span class="country">Jordan</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Diapride | Glemax | Piramyl</span>;</li>
<li>
<span class="countryCode">(JP)</span> <span class="country">Japan</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepiride amel | Glimepiride emec | Glimepiride ffp | Glimepiride isei | Glimepiride kn | Glimepiride ko | Glimepiride kyorin | Glimepiride me | Glimepiride mochida | Glimepiride Mylan | Glimepiride nissin | Glimepiride ohara | Glimepiride Pfizer | Glimepiride sandoz | Glimepiride sawai | Glimepiride takata | Glimepiride teva kowa | Glimepiride towa | Glimepiride ze | Glimepiride Zydus</span>;</li>
<li>
<span class="countryCode">(KE)</span> <span class="country">Kenya</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Azulix | Diaglim | Diapride | Getryl | Glide | Glimaryl | Glimeco | Glimed | Glimepiride denk | Glimestar | Glimiday | Glimulin | Glisen | Glorion | Glypin | Glyree | Limaryl | Perglim | Secrin | Ziglim</span>;</li>
<li>
<span class="countryCode">(KR)</span> <span class="country">Korea, Republic of</span><span class="countrySeparator">: </span><span class="drugName">Aberin | Ama | Amadiem | Amagreen | Amapil | Amaria | Amarid | Amaryl | Amed | Ameriad | Amerid | Amide | Amorin | Aprogen glimepiride | Aramyl | Armaphil | Aromyl | Aukomaryl | Bearyl | Celpiride | Climeril | Corinil | Crimeryl | Ctryl | Dagli | Daipiril | Dairid | Diabe | Diagril | Diamedy | Diaride | Diaryl | Dimaryl | Dimerid | Dimeril | Dmerid | Dymeryl | Dyryl | Emaryl | Euglex | Geride | Geripide | Gladiem | Gladin | Gladm | Gledin | Gliben | Glibeta | Glico | Glid | Glid m | Glida | Glidin | Glimarine | Glimaryl | Glimax | Glime | Glimed | Glimede | Glimedi | Glimel | Glimen | Glimep | Glimepid | Glimepide | Glimepidid | Glimepigen | Glimepil | Glimepin | Glimepiril | Glimepisyu | Glimeril | Glimerin | Glimeryl | Glimetin | Glimets | Glimetz | Glimewin | Glimid | Glimil | Glimin | Glion | Glipa | Glipam | Glipan | Glipico | Glipid | Glipidine | Glipil | Glipin | Glipion | Glipirin | Glipiron | Glipril | Glipydin | Glique | Glitec | Glopid | Glpid | Glube | Gludine | Gluless | Glupen | Glupid | Glyco | Glyone | Grid | Gril | Gripid | Hanmaryl | Iglid | Imaryl | Jeimaryl | Jr glimepiride | K Maril | Lax | Lipid | Lonaim | Lotra | Lowglico | Madmil | Mearyl | Mebid | Medirol | Mepigryl | Mepirid | Mepiril | Mepirin | Mepril | Mericle | Miaryl | Midia | Neomaryl | Neomaryl m | Newglipild | Newgril | Newmepirin | Pirame | Rax | Rimede | Samsung glimepiride | Unimaryl | Withus glimepiride</span>;</li>
<li>
<span class="countryCode">(KW)</span> <span class="country">Kuwait</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Diapride | G pride | Glim | Glimepirid hexal</span>;</li>
<li>
<span class="countryCode">(LB)</span> <span class="country">Lebanon</span><span class="countrySeparator">: </span><span class="drugName">Alpiride | Amaryl | Amepride | Diaberyl | Diaglim | Dialosa | Diameril | Diapride | Glemax | Glim | Glitra | Glypride | Irys | Orbide</span>;</li>
<li>
<span class="countryCode">(LT)</span> <span class="country">Lithuania</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimasol | Glimepirid Accord | Glimestada</span>;</li>
<li>
<span class="countryCode">(LU)</span> <span class="country">Luxembourg</span><span class="countrySeparator">: </span><span class="drugName">Amarylle | Glimepiride eg</span>;</li>
<li>
<span class="countryCode">(LV)</span> <span class="country">Latvia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Fertin | Glimasol | Glimepiride accord | Meglimid</span>;</li>
<li>
<span class="countryCode">(MA)</span> <span class="country">Morocco</span><span class="countrySeparator">: </span><span class="drugName">Aglim | Amarel | Glema | Glimewin | Glimiryl | Miliprel</span>;</li>
<li>
<span class="countryCode">(MX)</span> <span class="country">Mexico</span><span class="countrySeparator">: </span><span class="drugName">Adiripem | Amaryl | Apralix | Brimedan | Diapride | Esliby | Gleurix | Glimal | Glimepirida | Glimepirida Antibioticos | Glimepirida kendrick | Glimepirida loeffler | Lyramy | Zukedib</span>;</li>
<li>
<span class="countryCode">(MY)</span> <span class="country">Malaysia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Ameride | Axcel glimepiride | Getryl | Glenix | Glimaryl | Glimetor | Glimin | Glimpid | Glimulin | Intaszoryl | Limeral | Pricheck</span>;</li>
<li>
<span class="countryCode">(NG)</span> <span class="country">Nigeria</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Avropryl | Danprimide | Diapride | Getryl | Glemax | Glepid | Glibenax | Glimeryl | Glimestar | Glumril | Hobetic | Jempride | Meprid | Neroaryl | Perglim | Sam glimepiride</span>;</li>
<li>
<span class="countryCode">(NL)</span> <span class="country">Netherlands</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepiride a | Glimepiride cf | Glimepiride Merck | Glimepiride PCH | Glimepiride sandoz</span>;</li>
<li>
<span class="countryCode">(NO)</span> <span class="country">Norway</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepirid hexal | Glimepirid teva</span>;</li>
<li>
<span class="countryCode">(NZ)</span> <span class="country">New Zealand</span><span class="countrySeparator">: </span><span class="drugName">Amaryl</span>;</li>
<li>
<span class="countryCode">(PE)</span> <span class="country">Peru</span><span class="countrySeparator">: </span><span class="drugName">Amaglen | Amaryl | Amytrip | Diabeless | Diabemaryl | Glemaz | Glimebiotech | Glimepin | Glimepirida | Glimestalip | Glimide | Glyree | Novoglubin | Zoryl</span>;</li>
<li>
<span class="countryCode">(PH)</span> <span class="country">Philippines</span><span class="countrySeparator">: </span><span class="drugName">Acotril | Aforglim | Arya | Asaglim | Azutrol | Climeril | Diabeats | Diaberid | Diameride | Diamex | Geopride | Glimarex | Glimaryl | Glimauno | Glime m2 | Glimec | Glimep | Glimeryl | Glimesaph t2 | Glimesyn | Glimetrol | Glivarid | Glucozen | Glyper | Glyree | Kalbetic | Losugar | Neoglim | Norizec | Perglim | Rimepril | Soladin | Solosa | Stimulin | Syngly</span>;</li>
<li>
<span class="countryCode">(PK)</span> <span class="country">Pakistan</span><span class="countrySeparator">: </span><span class="drugName">Actigon | Amarox | Amaryl | Detove | Diabold | Diabryl | Diaglim | Diatrol | Dibi | Diryl | Econid | Evopride | Genlip | Getryl | Glactil | Glemex | Glemiwel | Glimefold | Glimera | Glimtide | Gliride | Glitop | Glory | Glow | Gluconorm | Glyset | Gulofin | Initial | Limerid | Limoride | Magpride | Maripride | Medipride | Megapride | Melnorm | Norlim | Orinase | Pamaryl | Raypride | Safgo | Steady | Sugral | Vpride | Zeprid | Zoryl</span>;</li>
<li>
<span class="countryCode">(PL)</span> <span class="country">Poland</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Avaron | Betaglid | Diaril | Glibezid | Glidiamid | Glimehexal | Glimepiride 1a pharma | Glimepiride accord | Glimepiride Arrow | Glimepiride Aurovitas | Glimepiride genoptim | Glimesan | Glimorion | Glitoprel | Pemidal | Symglic</span>;</li>
<li>
<span class="countryCode">(PR)</span> <span class="country">Puerto Rico</span><span class="countrySeparator">: </span><span class="drugName">Amaryl</span>;</li>
<li>
<span class="countryCode">(PT)</span> <span class="country">Portugal</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Diapiride | Glimepirida | Glimepirida Accord | Glimepirida aurobindo | Glimepirida aurovitas | Glimial</span>;</li>
<li>
<span class="countryCode">(PY)</span> <span class="country">Paraguay</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Dasten | Diencil | Glemaz | Glimedex | Glimepirida | Glimepirida dasanti | Glimepirida fapasa | Glimepirida milefar | Glipisin | Glu g | Hexan | Lipantyl | Panabutol | Pexeba</span>;</li>
<li>
<span class="countryCode">(QA)</span> <span class="country">Qatar</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Azulix | Diameril | Diapride | G-Pride | Glemax | Glim | Glimaryl | Glimpid | Glymride | Glypride | Piramyl</span>;</li>
<li>
<span class="countryCode">(RO)</span> <span class="country">Romania</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Amyx | Dibiglim | Glempid | Glime tad | Glimepirid | Glimepirid lph | Glimeran | Gliprex | Meglimid</span>;</li>
<li>
<span class="countryCode">(RU)</span> <span class="country">Russian Federation</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Diamerid | Glemauno | Glemaz | Glimepiride Canon | Glimepiride Canonpharma | Glimepiride sz | Glimepiride teva | Glumedex | Instolit | Meglimid</span>;</li>
<li>
<span class="countryCode">(SA)</span> <span class="country">Saudi Arabia</span><span class="countrySeparator">: </span><span class="drugName">Amaglime | Amaryl | G pride | Glemax | Glide | Glim | Glimaryl | Glimephan | Glitra | Glypride | Piramyl</span>;</li>
<li>
<span class="countryCode">(SE)</span> <span class="country">Sweden</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimepirid 2care4 | Glimepirid Actavis | Glimepirid alternova | Glimepirid bmm pharma | Glimepirid copyfarm | Glimepirid krka | Glimepirid mylan | Glimepirid orion | Glimepirid sandoz | Glimepirid stada</span>;</li>
<li>
<span class="countryCode">(SG)</span> <span class="country">Singapore</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Dialosa | Diapride</span>;</li>
<li>
<span class="countryCode">(SI)</span> <span class="country">Slovenia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Betaglid | Glimegamma</span>;</li>
<li>
<span class="countryCode">(SK)</span> <span class="country">Slovakia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Glimegamma | Glimep</span>;</li>
<li>
<span class="countryCode">(TH)</span> <span class="country">Thailand</span><span class="countrySeparator">: </span><span class="drugName">Amarax | Amaryl | Diaglip | Glazer | Glimepiride sandoz | Gliparil | Glypride | Losu | NIKP Glimepiride | Solosa</span>;</li>
<li>
<span class="countryCode">(TN)</span> <span class="country">Tunisia</span><span class="countrySeparator">: </span><span class="drugName">Amarel | Glimerel</span>;</li>
<li>
<span class="countryCode">(TR)</span> <span class="country">Turkey</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Diameprid | Glimax</span>;</li>
<li>
<span class="countryCode">(TW)</span> <span class="country">Taiwan</span><span class="countrySeparator">: </span><span class="drugName">Amalin | Amaride | Amarine | Amaryl | Glimaryl | Glimepine | Glipid | Glufar | Glusafe | Grumed | Lowmalin | Nonin</span>;</li>
<li>
<span class="countryCode">(UA)</span> <span class="country">Ukraine</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Dimaril | Eglim | Glemaz | Glianov | Glimaryl | Glimax | Glimepirid | Glimepirid teva | Glimepiride indar | Glinova | Melpamid</span>;</li>
<li>
<span class="countryCode">(UG)</span> <span class="country">Uganda</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Azulix | Diapride | Euglim | Glimepiride denk | Glimeryl | Glypride | Perglim</span>;</li>
<li>
<span class="countryCode">(UY)</span> <span class="country">Uruguay</span><span class="countrySeparator">: </span><span class="drugName">Adiuvan | Amaryl | Euclamide | Glimepirida | Manarel</span>;</li>
<li>
<span class="countryCode">(VE)</span> <span class="country">Venezuela, Bolivarian Republic of</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Diabutil | Dimavyl | Glimepir | Glimepirida | Glimirid | Glimy | Gliperim | Glucodan | Glypride | Piglifar</span>;</li>
<li>
<span class="countryCode">(VN)</span> <span class="country">Viet Nam</span><span class="countrySeparator">: </span><span class="drugName">Agludril | Amapileo | Amapirid | Binexamorin | Canzeal | Flodilan | Genprid | Geride | Glimegim | Glimvaz | Glumerif | Mekoaryl | Necaral | Oramep | Savdiaride</span>;</li>
<li>
<span class="countryCode">(ZA)</span> <span class="country">South Africa</span><span class="countrySeparator">: </span><span class="drugName">Accord Glimepiride | Amaryl | Aspen glimepiride | Austell glimepirid | Austell glimepiride | Glamaryl | Sulphonur | Zydus glimepiride</span>;</li>
<li>
<span class="countryCode">(ZM)</span> <span class="country">Zambia</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Azulix | Diapride | Gimetab | Glimcip | Glimepiride denk | Glimestar | Glimulin | Glyree</span>;</li>
<li>
<span class="countryCode">(ZW)</span> <span class="country">Zimbabwe</span><span class="countrySeparator">: </span><span class="drugName">Amaryl | Azulix | Glimulin 1 | Glimulin 2 | Glipiryl</span></li></ul></div>
</div>
</div>
</div>
</div><div class="headingAnchor" id="references"><ol id="reference">
<li>
<div class="reference" id="lexi-content-ref-37139824">
<a name="37139824"></a>2023 American Geriatrics Society Beers Criteria Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria for potentially inappropriate medication use in older adults. <i>J Am Geriatr Soc</i>. 2023;71(7):2052-2081. doi:10.1111/jgs.18372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/37139824/pubmed" id="37139824" target="_blank">37139824</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31087027">
<a name="31087027"></a>Alexopoulos AS, Blair R, Peters AL. Management of preexisting diabetes in pregnancy: a review. <i>JAMA</i>. 2019;321(18):1811-1819. doi:10.1001/jama.2019.4981<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/31087027/pubmed" id="31087027" target="_blank">31087027</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Amaryl.1">
<a name="Amaryl.1"></a>Amaryl (glimepiride) [prescribing information]. Bridgewater, NJ: Sanofi-Aventis; December 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.1">
<a name="ADA.1"></a>American Diabetes Association (ADA). Standards of care in diabetes–2023. <i>Diabetes Care</i>. 2023;46(suppl 1):S1-S291. https://diabetesjournals.org/care/issue/46/Supplement_1. Accessed January 4, 2023.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-ADA.2">
<a name="ADA.2"></a>American Diabetes Association (ADA). Standards of medical care in diabetes–2022. <i>Diabetes Care</i>. 2022;45(suppl 1):S1-S258. https://diabetesjournals.org/care/issue/45/Supplement_1. Accessed October 13, 2022.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Apotex.1">
<a name="Apotex.1"></a>Apo-Glimepiride (glimepiride) [product monograph]. Toronto, Ontario, Canada: Apotex Inc; October 2018.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25590212">
<a name="25590212"></a>Apovian CM, Aronne LJ, Bessesen DH, et al; Endocrine Society. Pharmacological management of obesity: an Endocrine Society clinical practice guideline [published correction appears in <i>J Clin Endocrinol Metab</i>. 2015;100(5):2135-2136]. <i>J Clin Endocrinol Metab</i>. 2015;100(2):342-362. doi: 10.1210/jc.2014-3415<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/25590212/pubmed" id="25590212" target="_blank">25590212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10994361">
<a name="10994361"></a>Balaguer Santamaría JA, Feliu Rovira A, Escribano Subias J, et al. Persistent hyperinsulinemic hypoglycemia in newborn associated with glimepiride treatment at the beginning of pregnancy. <i>Rev Clin Esp</i>. 2000;200(7):399-400.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/10994361/pubmed" id="10994361" target="_blank">10994361</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-24194617">
<a name="24194617"></a>Blumer I, Hadar E, Hadden DR, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2013;98(11):4227-4249.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/24194617/pubmed" id="24194617" target="_blank">24194617</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23688537">
<a name="23688537"></a>Bogun M, Inzucchi SE. Inpatient management of diabetes and hyperglycemia. <i>Clin Ther</i>. 2013;35(5):724-733. doi:10.1016/j.clinthera.2013.04.008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/23688537/pubmed" id="23688537" target="_blank">23688537</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15303450">
<a name="15303450"></a>Brackett CC, Singh H, Block JH. Likelihood and mechanisms of cross-allergenicity between sulfonamide antibiotics and other drugs containing a sulfonamide functional group. <i>Pharmacotherapy</i>. 2004;24(7):856-870.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/15303450/pubmed" id="15303450" target="_blank">15303450</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30291106">
<a name="30291106"></a>Davies MJ, D'Alessio DA, Fradkin J, et al. Management of hyperglycemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <i>Diabetes Care</i>. 2018;41(12):2669-2701. doi:10.2337/dci18-0033<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/30291106/pubmed" id="30291106" target="_blank">30291106</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10454950">
<a name="10454950"></a>DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. <i>Ann Intern Med</i>. 1999;131(4):281-303. doi:10.7326/0003-4819-131-4-199908170-00008<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/10454950/pubmed" id="10454950" target="_blank">10454950</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-25132212">
<a name="25132212"></a>Del Prato S, Camisasca R, Wilson C, Fleck P. Durability of the efficacy and safety of alogliptin compared with glipizide in type 2 diabetes mellitus: a 2-year study.<i> Diabetes Obes Metab</i>. 2014;16(12):1239-1246. doi:10.1111/dom.12377<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/25132212/pubmed" id="25132212" target="_blank">25132212</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-DiabetesCAN.1">
<a name="DiabetesCAN.1"></a>Diabetes Canada Clinical Practice Guidelines Expert Committee. Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada. <i>Can J Diabetes.</i> 2018;42(suppl 1):S1-S325.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9742977">
<a name="9742977"></a>“Effect of Intensive Blood-Glucose Control With Metformin on Complications in Overweight Patients With Type 2 Diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group,” <i>Lancet</i>, 1998, 352(9131):854-65.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/9742977/pubmed" id="9742977" target="_blank">9742977</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32736942">
<a name="32736942"></a>Egan AM, Dow ML, Vella A. A review of the pathophysiology and management of diabetes in pregnancy. <i>Mayo Clin Proc</i>. 2020;95(12):2734-2746. doi:10.1016/j.mayocp.2020.02.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/32736942/pubmed" id="32736942" target="_blank">32736942</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Expert.DOR">
<a name="Expert.DOR"></a>Expert opinion. Senior Renal Editorial Team: Bruce Mueller, PharmD, FCCP, FASN, FNKF; Jason A. Roberts, PhD, BPharm (Hons), B App Sc, FSHP, FISAC; Michael Heung, MD, MS.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32022600">
<a name="32022600"></a>Garber AJ, Handelsman Y, Grunberger G, et al. Consensus statement by the American Association of Clinical Endocrinologists and American College of Endocrinology on the comprehensive type 2 diabetes management algorithm - 2020 executive summary. <i>Endocr Pract</i>. 2020;26(1):107-139. doi:10.4158/CS-2019-0472<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/32022600/pubmed" id="32022600" target="_blank">32022600</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27967230">
<a name="27967230"></a>Gianchandani RY, Neupane S, Iyengar JJ, Heung M. Pathophysiology and management of hypoglycemia end-stage renal disease patients: a review. <i>Endocr Pract</i>. 2017;23(3):353-362. doi:10.4158/EP161471.RA<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/27967230/pubmed" id="27967230" target="_blank">27967230</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8842603">
<a name="8842603"></a>Goldberg RB, Holvey SM, Schneider J. A dose-response study of glimepiride in patients with NIDDM who have previously received sulfonylurea agents. The Glimepiride Protocol #201 Study Group. <i>Diabetes Care</i>. 1996;19(8):849-856. doi:10.2337/diacare.19.8.849<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/8842603/pubmed" id="8842603" target="_blank">8842603</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-17079764">
<a name="17079764"></a>Inzucchi SE. Clinical practice. Management of hyperglycemia in the hospital setting. <i>N Engl J Med</i>. 2006;355(18):1903-1911. doi:10.1056/NEJMcp060094<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/17079764/pubmed" id="17079764" target="_blank">17079764</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15644481">
<a name="15644481"></a>Johnson KK, Green DL, Rife JP, Limon L. Sulfonamide cross-reactivity: fact or fiction? [published correction appears in Ann Pharmacother. 2005;39(7-8):1373]. A<i>nn Pharmacother</i>. 2005;39(2):290-301.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/15644481/pubmed" id="15644481" target="_blank">15644481</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15806235">
<a name="15806235"></a>Kalyoncu NI, Yaris F, Kadioglu M, et al. Pregnancy outcome following exposure to orlistat, ramipril, glimepiride in a woman with metabolic syndrome. <i>Saudi Med J</i>. 2005;26(3):497-499.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/15806235/pubmed" id="15806235" target="_blank">15806235</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-32998798">
<a name="32998798"></a>Kidney Disease: Improving Global Outcomes (KDIGO) Diabetes Work Group. KDIGO 2020 clinical practice guideline for diabetes management in chronic kidney disease. <i>Kidney Int</i>. 2020;98(4S):S1-S115. doi:10.1016/j.kint.2020.06.019<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/32998798/pubmed" id="32998798" target="_blank">32998798</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19417773">
<a name="19417773"></a>Korner J, Inabnet W, Febres G, et al. Prospective study of gut hormone and metabolic changes after adjustable gastric banding and Roux-en-Y gastric bypass. <i>Int J Obes (Lond).</i> 2009;33(7):786-795. doi: 10.1038/ijo.2009.79<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/19417773/pubmed" id="19417773" target="_blank">19417773</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-30903688">
<a name="30903688"></a>LeRoith D, Biessels GJ, Braithwaite SS, et al. Treatment of diabetes in older adults: an Endocrine Society clinical practice guideline. <i>J Clin Endocrinol Metab</i>. 2019;104(5):1520-1574. doi: 10.1210/jc.2019-00198.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/30903688/pubmed" id="30903688" target="_blank">30903688</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31917200">
<a name="31917200"></a>Mechanick JI, Apovian C, Brethauer S, et al. Clinical practice guidelines for the perioperative nutrition, metabolic, and nonsurgical support of patients undergoing bariatric procedures - 2019 update: cosponsored by American Association of Clinical Endocrinologists/American College of Endocrinology, the Obesity Society, American Society for Metabolic &amp; Bariatric Surgery, Obesity Medicine Association, and American Society of Anesthesiologists. <i>Surg Obes Relat Dis</i>. 2020;16(2):175-247. doi:10.1016/j.soard.2019.10.025<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/31917200/pubmed" id="31917200" target="_blank">31917200</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-27568471">
<a name="27568471"></a>Mingrone G, Cummings DE. Changes of insulin sensitivity and secretion after bariatric/metabolic surgery. <i>Surg Obes Relat Dis</i>. 2016;12(6):1199-1205. doi: 10.1016/j.soard.2016.05.013.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/27568471/pubmed" id="27568471" target="_blank">27568471</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-19454396">
<a name="19454396"></a>Moghissi ES, Korytkowski MT, DiNardo M, et al; American Association of Clinical Endocrinologists; American Diabetes Association. American Association of Clinical Endocrinologists and American Diabetes Association consensus statement on inpatient glycemic control. <i>Endocr Pract</i>. 2009;15(4):353-369. doi:10.4158/EP09102.RA<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/19454396/pubmed" id="19454396" target="_blank">19454396</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-28465376">
<a name="28465376"></a>Neumiller JJ, Alicic RZ, Tuttle KR. Therapeutic considerations for antihyperglycemic agents in diabetic kidney disease. <i>J Am Soc Nephrol</i>. 2017;28(8):2263-2274. doi:10.1681/ASN.2016121372<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/28465376/pubmed" id="28465376" target="_blank">28465376</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-12235454">
<a name="12235454"></a>Niemi M, Cascorbi I, Timm R, et al, "Glyburide and glimepiride pharmacokinetics in subjects with different CYP2C9 genotypes," <i>Clin Pharmacol Ther</i>, 2002, 72(3):326-32.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/12235454/pubmed" id="12235454" target="_blank">12235454</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-22354457">
<a name="22354457"></a>Peterli R, Steinert RE, Woelnerhanssen B, et al. Metabolic and hormonal changes after laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, prospective trial. <i>Obes Surg</i>. 2012;22(5):740-748. doi: 10.1007/s11695-012-0622-3.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/22354457/pubmed" id="22354457" target="_blank">22354457</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Manu.1">
<a name="Manu.1"></a>Refer to manufacturer's labeling.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-10605995">
<a name="10605995"></a>Riddle MC. Oral pharmacologic management of type 2 diabetes. <i>Am Fam Physician</i>. 1999;60(9):2613-2620.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/10605995/pubmed" id="10605995" target="_blank">10605995</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8960852">
<a name="8960852"></a>Rosenkranz B, Profozic V, Metelko Z, Mrzljak V, Lange C, Malerczyk V. Pharmacokinetics and safety of glimepiride at clinically effective doses in diabetic patients with renal impairment. <i>Diabetologia</i>. 1996;39(12):1617-1624. doi:10.1007/s001250050624<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/8960852/pubmed" id="8960852" target="_blank">8960852</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-31536101">
<a name="31536101"></a>Rosenstock J, Kahn SE, Johansen OE, et al; CAROLINA Investigators. Effect of linagliptin vs glimepiride on major adverse cardiovascular outcomes in patients with type 2 diabetes: the CAROLINA randomized clinical trial. <i>JAMA</i>. 2019;322(12):1155-1166. doi: 10.1001/jama.2019.13772.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/31536101/pubmed" id="31536101" target="_blank">31536101</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-8908379">
<a name="8908379"></a>Rosenstock J, Samols E, Muchmore DB, Schneider J. Glimepiride, a new once-daily sulfonylurea. A double-blind placebo-controlled study of NIDDM patients. Glimepiride Study Group.<i> Diabetes Care</i>. 1996;19(11):1194-1199. doi:10.2337/diacare.19.11.1194<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/8908379/pubmed" id="8908379" target="_blank">8908379</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-37150579">
<a name="37150579"></a>Samson SL, Vellanki P, Blonde L, et al. American Association of Clinical Endocrinology consensus statement: comprehensive type 2 diabetes management algorithm - 2023 update. <i>Endocr Pract</i>. 2023;29(5):305-340. doi:10.1016/j.eprac.2023.02.001<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/37150579/pubmed" id="37150579" target="_blank">37150579</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15242722">
<a name="15242722"></a>Slatore CG, Tilles SA. Sulfonamide hypersensitivity. <i>Immunol Allergy Clin North Am</i>. 2004;24(3):477-490.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/15242722/pubmed" id="15242722" target="_blank">15242722</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-23222033">
<a name="23222033"></a>Tandra S, Chalasani N, Jones DR, Mattar S, Hall SD, Vuppalanchi R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. <i>Ann Surg</i>. 2013;258(2):262-269. doi: 10.1097/SLA.0b013e31827a0e82<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/23222033/pubmed" id="23222033" target="_blank">23222033</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-15373844">
<a name="15373844"></a>Tornero P, De Barrio M, Baeza ML, Herrero T. Cross-reactivity among p-amino group compounds in sulfonamide fixed drug eruption: diagnostic value of patch testing. <i>Contact Dermatitis</i>. 2004;51(2):57-62.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/15373844/pubmed" id="15373844" target="_blank">15373844</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-9742976">
<a name="9742976"></a>UK Prospective Diabetes Study (UKPDS) Group. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) [published correction appears in: <i>Lancet.</i> 1999;354(9178):602]. <i>Lancet</i>. 1998;352(9131):837-853.<span class="pubmed-id"> [PubMed <a href="https://www.uptodate.com/contents/glimepiride-drug-information/abstract-text/9742976/pubmed" id="9742976" target="_blank">9742976</a>]</span>
</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.1">
<a name="Wexler.1"></a>Wexler DJ. Initial management of hyperglycemia in adults with type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021a.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.2">
<a name="Wexler.2"></a>Wexler DJ. Management of persistent hyperglycemia in type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed September 18, 2020.</div>
</li>
<li>
<div class="reference" id="lexi-content-ref-Wexler.3">
<a name="Wexler.3"></a>Wexler DJ. Sulfonylureas and meglitinides in the treatment of type 2 diabetes mellitus. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. <a href="http://www.uptodate.com" target="_blank">http://www.uptodate.com</a>. Accessed October 13, 2021b.</div>
</li></ol></div><div id="topicVersionRevision">Topic 8491 Version 460.0</div></div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
